FCGR2A and neoplasm: ICIs can modulate the tumour immune microenvironment through FcγR-dependent mechanisms, as mentioned for anti-CTLA-4 mAbs and depletion of Treg, or anti PD-L1 avelumab and myeloid subset composition.